GLP-1 Drugs and Your Eyes: NAION, Diabetic Retinopathy, and Retinal Blockages

GLP-1 drugs such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are linked to three separate eye conditions, and they point in different directions.

The first is NAION, a sudden loss of blood flow to the optic nerve that can take away part of the vision in one eye. Europe's drug regulator has called it a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. The second is diabetic retinopathy, damage to the blood vessels at the back of the eye in people with diabetes. When blood sugar drops quickly, existing retinopathy can get worse for a time, and the drug labels warn about this. The third is retinal vascular occlusion, a blockage of a vein or artery in the retina. A new records study found it was less common in people taking GLP-1 drugs.

None of these conditions is common, and for most people the heart, kidney, and weight benefits of these drugs are much larger than the eye risks. The practical message is simple: if you have diabetic eye disease, tell your prescriber before you start, and get urgent care for any sudden change in vision.

These conditions affect different parts of the eye, which is why the news about them can seem to conflict.

The optic nerve carries signals from the eye to the brain. NAION, short for non-arteritic anterior ischemic optic neuropathy, happens when blood flow to the front of this nerve drops suddenly. People usually notice painless dimming or blurring in one eye, often on waking, and no treatment reliably restores the lost vision.

The retina is the thin layer of light-sensing tissue at the back of the eye. In diabetic retinopathy, years of high blood sugar damage its small blood vessels, which can leak or grow abnormally. It usually develops slowly over years.

A retinal vascular occlusion is a clot or blockage in one of the retina's veins or arteries, similar to a small stroke in the eye. It can cause sudden blurring or loss of part of the visual field.

Concern about NAION began with a 2024 study from Massachusetts Eye and Ear and grew as larger studies looked at the question. In June 2025, the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide. It said large studies in adults with type 2 diabetes showed about a two-fold higher risk than in people not taking the drug, which works out to about one extra case for every 10,000 years of treatment.

The UK's drug regulator issued its own warning in February 2026. It told doctors to send anyone with sudden vision loss on semaglutide for an urgent eye exam and to stop the drug if NAION is confirmed. As of October 2026, the U.S. labels for Ozempic and Mounjaro do not list NAION.

The evidence for tirzepatide is weaker than for semaglutide, and studies have not settled whether the risk applies to every GLP-1 drug. Our NAION guide covers the studies, the regulators' decisions, and the absolute numbers in more detail.

This risk has the longest record. In SUSTAIN-6, a two-year trial of semaglutide in 3,297 people with type 2 diabetes and high heart risk, published in 2016, complications of diabetic retinopathy occurred in 3.0% of people on semaglutide and 1.8% on placebo, according to the Ozempic label. The extra risk was concentrated in people who already had retinopathy: 8.2% versus 5.2%, compared with 0.7% versus 0.4% in people without it.

The labels for Ozempic and Mounjaro explain the likely reason. A rapid improvement in blood sugar has been tied to a temporary worsening of diabetic retinopathy, a pattern doctors had seen before with insulin. Mounjaro's label added this warning in August 2026, and both labels say people with a history of diabetic retinopathy should be monitored for progression.

What happens over the long run is less clear. The Ozempic label says the long-term effect of semaglutide on retinopathy has not been studied. Novo Nordisk's FOCUS trial, which is testing semaglutide against placebo in about 1,500 people with type 2 diabetes and measuring eye changes over five years, is not expected to finish until late 2027.

A study published on October 17, 2026 in the Journal of VitreoRetinal Diseases looked at the question from the other side. Researchers at Case Western Reserve University and the Cleveland Clinic's Cole Eye Institute used a large U.S. health-records database to compare adults with type 2 diabetes who took GLP-1 drugs with matched adults who took other diabetes medicines.

People on GLP-1 drugs had a lower risk of any retinal vascular occlusion at one year (hazard ratio 0.66), three years (0.71), and five years (0.79). A hazard ratio of 0.66 means the event happened about one-third less often. The study included 53,413 matched pairs at one year and 14,695 at five years.

This is an observational study, so it shows a link, not proof that the drugs prevented blockages. People who get GLP-1 drugs may differ in ways the matching did not capture. The authors called for prospective trials.

The labels and regulators point to a few groups who should talk with their prescriber before starting or while taking these drugs.

People with known diabetic retinopathy face the clearest risk, because that is where the extra complications in SUSTAIN-6 occurred. Ask whether you need an eye exam before you start and how often you should be checked during the first months, when blood sugar falls the most.

People with risk factors for NAION, such as older age, high blood pressure, sleep apnea, diabetes, or a past NAION in one eye, may want to discuss the European and UK warnings with their doctor, especially if they are considering semaglutide.

Anyone who gets a GLP-1 drug through a private clinic or telehealth service should make sure their regular doctor and eye doctor know about it. The UK regulator noted that privately prescribed semaglutide may not appear in a patient's medical record.

Sudden loss of vision, a dark or blurry area in part of your sight, or rapidly worsening eyesight in one eye needs same-day medical care. Go to an emergency department or an eye clinic, and tell them you take a GLP-1 drug.

Do not stop the drug on your own. Stopping can raise blood sugar and blood pressure, and the decision depends on what the eye exam finds. European and UK regulators advise stopping semaglutide if NAION is confirmed.

Questions to ask your prescriber:

• Do I have diabetic retinopathy, and should I see an eye doctor before starting?
• How fast will my dose increase, and how quickly is my blood sugar likely to fall?
• Do my risk factors for NAION change which drug you would choose?
• How often should I have my eyes checked while I take this drug?

For a list of what each GLP-1 drug is approved to treat, see our guide to GLP-1 drugs and their approved uses.